Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772219 | 0.93 | S1PR1 (0.47) | S1PR1S1PR3 | |
| SCHEMBL2456700 | 0.89 | S1PR1 (0.44) | S1PR1S1PR3 | |
| SCHEMBL2459261 | 0.85 | S1PR1 (0.47) | S1PR1S1PR3 | |
| SCHEMBL2462250 | 0.83 | S1PR1 (0.42) | S1PR1S1PR3 | |
| SCHEMBL13002073 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3 | |
| SCHEMBL2457233 | 0.80 | MAOB (0.48) | S1PR1S1PR3 | |
| SCHEMBL2463977 | 0.79 | S1PR1 (0.41) | S1PR1S1PR3 | |
| SCHEMBL2454474 | 0.79 | S1PR1 (0.41) | S1PR1S1PR3 | |
| SCHEMBL2462477 | 0.78 | MAPT (0.48) | S1PR1S1PR3 | |
| SCHEMBL2454104 | 0.77 | CACNA1G (0.41) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863475-B1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-7846964-B2 | Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20080194670-A1 | Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863475-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100635-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194670-A1 | Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists | GRK2, GRK4, GPR174 | S1PR1 19/4885S1PR3 77/4885TUBB1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.